Triple negative breast cancer (TNBC) is one of many forms of breast cancer.
Forms of breast cancer are generally diagnosed based on the presence or absence of three “receptors” known to fuel most breast cancer tumors: estrogen, progesterone and HER2-neu.
A diagnosis of TNBC means that the tumor in question is estrogenreceptor negative, progesterone-receptor negative and Her2-negative. In other words, triple negative breast cancer tumors do not exhibit any of the three known receptors.
Receptor-targeting therapies have fueled tremendous recent advances in the fight against breast cancer. Unfortunately, there is no such targeted therapy for triple negative breast cancer.
TNBC tends to be more aggressive, more likely to recur, and more difficult to treat because there is no targeted treatment.
TNBC disproportionately strikes younger women, women of African, Latina or Caribbean descent, and those with BRCA1 mutations.
Approximately every half hour, another woman in the US is diagnosed with triple negative breast cancer.